OctoPlus N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 10 mrt 2011 - 07:28

Statutaire naam OctoPlus N.V.

Titel OctoPlus' licensee Biolex to present final results of Locteron Phase IIb study at EASL conference

Bericht Presentations will highlight strong antiviral activity and SVR rates together with significant reductions in flu-like adverse events and reduced rates of depression Leiden, the Netherlands, 10 March 2011 - OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that two abstracts by its licensee Biolex Therapeutics have been accepted for presentation on 31 March at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201103100000000004_OctoPlus' licensee Biolex to present final results of Locteron Phase IIb study at EASL conference.pdf (opens in a new window)

201103100000000004_OctoPlus' licentiepartner Biolex zal eindresultaten Locteron Fase IIb studie presenteren tijdens EASL congres.pdf (opens in a new window)

Datum laatste update: 05 februari 2026